Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ Preservation in Locally Advanced Rectal Adenocarcinoma Using SCRT and Chemotherapy
NCT04703101Phase 1Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Feb 2021
- Primary completion
- Jul 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and capecitabine in rectal adenocarcinoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Complete clinical response rate up to 5 years. Started Feb 2021; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatincapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT04703101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703101.